bioAffinity Technologies, Inc. (BIAF)

NCM – Real vaqt narxi. Valyuta: USD

0.47

-0.01 (-2.74%)

Yopilishda: Aug 12, 2026, 4:00 PM EDT

0.47

-0.00 (-0.47%)

Bozordan keyin: Aug 12, 2026, 5:18 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

07.08.2026

bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung

SAN ANTONIO, Texas--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies reported second quarter 2026 financial results and continued commercial momentum for CyPath® Lung test for lung cancer.

Videolar

No Data

There is no data to display

Press-relizlar

07.08.2026

bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung

SAN ANTONIO, Texas--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies reported second quarter 2026 financial results and continued commercial momentum for CyPath® Lung test for lung cancer.

bioAffinity Technologies, Inc. (BIAF)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

bioAffinity Technologies, Inc. (BIAF)

bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung

Videolar

No Data

Press-relizlar

bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung

bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung

Videolar

No Data

Press-relizlar

bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung

Search stocks

bioAffinity Technologies, Inc. (BIAF)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

bioAffinity Technologies, Inc. (BIAF)

bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung

Videolar

No Data

Press-relizlar

bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung

bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung

Videolar

No Data

Press-relizlar

bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung